Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.40 |
| ▸ | IDH1 | O75874 | 3/20 | 0.31 |
| ▸ | PDE9A | O76083 | 2/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7906936 | 0.92 | CRBN (0.40) | CRBNPDE9APLAT | |
| SCHEMBL7907820 | 0.90 | PDE9A (0.33) | PDE9A | |
| SCHEMBL12044761 | 0.90 | CRBN (0.39) | CRBN | |
| SCHEMBL12044910 | 0.88 | PDE9A (0.32) | PDE9A | |
| SCHEMBL12044931 | 0.87 | CRBN (0.38) | CRBN | |
| SCHEMBL7908894 | 0.87 | CRBN (0.41) | CRBN | |
| SCHEMBL7896981 | 0.85 | CRBN (0.37) | CRBNIDH1PDE9A | |
| SCHEMBL1721972 | 0.84 | BRD4 (0.37) | PLAT | |
| SCHEMBL7899537 | 0.84 | AVPR2 (0.38) | PDE9APLATAVPR1A | |
| Hydrochloric Acid SCHEMBL9979346 | 0.84 | BRD4 (0.37) | PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085134-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20130085134-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8357688-B2 | Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2013-01-22 | — | — | US | disclosed |
| US-8357688-B2 | Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2013-01-22 | — | — | US | disclosed |
| US-20110319385-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319385-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085134-A1 | QUINOXALINE COMPOUND | PDE9A, PDE2A, PDE3A | CRBN 4462/4885IDH1 970/4885PDE9A 1/4885 |
| US-20110319385-A1 | QUINOXALINE COMPOUND | PDE9A, PDE5A, PDE3A | CRBN 3942/4885IDH1 1032/4885PDE9A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.